Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bayer’s thrombosis drug filed for approval in US
The new drug application (NDA) seeks approval for the use of rivaroxaban in the prevention of deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee
The new drug application (NDA) seeks approval for the use of rivaroxaban in the prevention of deep vein thrombosis and pulmonary embolism in patients undergoing hip or knee
The patent protects methods of treating leukemia with LOR-2040, both alone and in combination with chemotherapy drugs. The patent also covers methods of treating specific solid cancers with
The small business innovation research (SBIR) grant will support research and development efforts to genetically engineer mosquitoes that can enhance Sanaria’s whole-parasite malaria vaccine production process. David O’Brochta,
The company will seek clarification from the FDA of its position and of the additional information required to obtain final marketing approval. UCB confirmed that lacosamide (Vimpat) is
The company has entered into subscription agreements with certain current, new institutional shareholders and affiliates of the company to sell 6.68 million units which are comprised of one
Mr Molloy has 20 years of medical device experience in large corporations and venture funded businesses at the senior management level. He began his career as a certified
This over-the-counter product is used for the reduction and control of gastrointestinal symptoms that are produced by excessive acid secretion and is also helpful in the treatment of
The BrainLAB Monte Carlo dose calculation software is a high performance Monte Carlo algorithm for therapeutic photon beams supporting nearly all linear accelerator and multi-leaf collimator (MLC) types.
The company reported worldwide sales of $5.15 billion in the second quarter of 2008, an increase of 11%, compared with $4.63 billion in the corresponding period of 2007.
The FDA stated that Vanda had demonstrated the effectiveness of iloperidone at 24mg/day in the 3101 study for which the company reported results in December 2006, and that